Competitor Analysis ErbB / Her Receptor Antagonists

Publisher: La Merie Publishing
Pages: 168
Format: PDF
Product Line:
Competitor Analysis
Product Line:
Target Pipeline
Product Code: LMCA0130
Release Date: July of 2013

650.00 €
Free of 21 % VAT (except in Spain and also in the European Union without valid intl. VAT no),
Delivery costs do not apply or are included.
You can also order this product via email or fax , please download the Order Form
Need more information?
Ask a question about this product

Competitor Analysis ErbB / Her Receptor Antagonists

Product description

The present Competitive Intelligence Report about antagonists of the ErbB/Her receptor pathway provides a competitor evaluation in the field of ErbB1 (EGF-R), ErbB2 (Her), ErbB3 (Her) and ErbB4 (Her4) receptor targeting molecules for treatment of cancer as of July 2013. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Targeted treatment of EGF-R and Her2-positive cancers with target specific antibodies has become an example of successful personalized medicine. The commercial success of small molecule ErbB/Her receptor tyrosine kinase inhibitors and EGF-R and Her2 targeted antibody  therapy has spurred the discovery and development of efficacy enhanced versions as well as of ErbB dual or multi-target therapies.

The report includes a compilation of current active projects in research and development of molecules targeting the receptors of the ErbB/Her family. In addition the report lists company-specific R&D pipelines of ErbB/Her receptor targeting molecular entities. Competitor projects are listed in a tabular format providing information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.


Competitor Analysis ErbB / Her Receptor Antagonists

Table of Contents

  • Sales of Small Molecules Inhibitors of the ErbB/Her Receptor Family
  • Sales of Antibodies Targeting ErbB/Her Receptors

1) Small Molecules Targeting the ErbB/Her Receptor Family
a) Selective EGF-R Tyrosine Kinase (TK) Inhibitors
- Tarceva Pipeline
- Iressa Pipeline
- Pipeline of Other EGF-R Selective TK Inhibitors
b) Selective Her2 (ErbB2) TK Inhibitors
c) Dual EGF-R (ErbB1) and Her2 (ErbB2) TK Inhibitors
- Tykerb  Pipeline
- Pipeline of Other Dual EGF-R (ErbB1) and Her2 (ErbB2) TK Inhibitors
d) Pan-Her (EGF-R, Her2 and Her4) / pan-Erb (ErbB1, ErbB2, ErbB4) TK Inhibitors
- Gilotrif Pipeline
- Neratinib Pipeline
- Dacomitinb Pipeline
- Poziotinib Pipeline
- Pipeline of Other Pan-Her Tk Inhibitors
e) Multi-Target TK Inhibitors incl. EGF-R (ErbB1) Inhibition
f) Multi-Target TK Inhibitors incl. EGF-R (ErbB1) and Her2 (ErbB2) Inhibition

2) Biologics (Cells, Proteins, RNA) Targeting the ErbB/Her Receptor Family

3) Vaccines Targeting the ErbB/Her Receptor Family
a) EGF-R (ErbB1) Vaccines
b) Her2 (ErbB2) Vaccines
c) Her3 (ErbB3) Vaccines

4) Antibodies Targeting the ErbB/Her Receptor Family
a) Selective EGF-R (ErbB1) Antibodies
- Erbitux Pipeline
- Vectibix Pipeline
- Nimotuzumab Pipeline
- Pipeline of Other Selective EGF-R (ErbB1) Antibodies
- Biosimilar Cetuximab Pipeline
- Biosimilar Panitumumab Pipeline

b) Selective Her2 (ErbB2) Antibodies
- Herceptin Pipeline
- Perjeta Pipeline
- Kadcyla Pipeline
- Pipeline of Other Selective Her2 (ErbB2) Antibodies
- Biosimilar Trastuzumab Pipeline
c) Selective Her3 (ErbB3) Antibodies
d) Dual and Pan ErbB / Her Antibodies
e) Dual Target Antibodies incl. ErbB/Her Receptor Antagonism

5) Corporate ErbB/Her Receptor Antagonist R&D Pipelines

The above shown price refers to a Single User License. Please contact us for prices of departmental, site or global product licenses.

This Report is NOT a downloadable item but will be delivered via email within 24 h (working days only).

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up